MetroGel

See also: Generic MetroCream, Generic MetroGel-Vaginal, Generic MetroLotion

MetroGel is a brand name of metronidazole topical, approved by the FDA in the following formulation(s):

METROGEL (metronidazole - gel; topical)

• 
  Manufacturer: GALDERMA LABS LP
  
  Approval date: November 22, 1988
  
  Strength(s): 0.75% ^[RLD][AB]


• 
  Manufacturer: GALDERMA LABS LP
  
  Approval date: June 30, 2005
  
  Strength(s): 1% ^[RLD][AB]

Has a generic version of MetroGel been approved?

A generic version of MetroGel has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to MetroGel and have been approved by the FDA:

metronidazole gel; topical

• 
  Manufacturer: FOUGERA PHARMS
  
  Approval date: June 6, 2006
  
  Strength(s): 0.75% ^[AB]


• 
  Manufacturer: G AND W LABS INC
  
  Approval date: January 19, 2011
  
  Strength(s): 0.75% ^[AB]


• 
  Manufacturer: TARO
  
  Approval date: July 18, 2006
  
  Strength(s): 0.75% ^[AB]


• 
  Manufacturer: TOLMAR
  
  Approval date: July 13, 2006
  
  Strength(s): 0.75% ^[AB]


• 
  Manufacturer: TOLMAR
  
  Approval date: July 22, 2011
  
  Strength(s): 1% ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of MetroGel. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Aqueous compositions containing metronidazole
  Patent 6,881,726
  Issued: April 19, 2005
  Inventor(s): Chang; Yunik & Dow; Gordon J.
  Assignee(s): Dow Pharmaceutical Sciences
  An aqueous solution of metronidazole in which the concentration of metronidazole is higher than 0.75%. The solution contains a combination of solubility-enhancing agents, one of which is a cyclodextrin such as beta-cyclodextrin and the second is a compound other than a cyclodextrin. Methods of manufacture and therapeutic use of the solution are disclosed.
  
  Patent expiration dates:
  
  
  • February 21, 2022
    
    ✓ 
    Patent use: ONCE A DAY TOPICAL TREATMENT OF THE INFLAMMATORY LESIONS OF ROSACEA
    ✓ 
    Drug product
  
  



• 
  Aqueous compositions containing metronidazole
  Patent 7,348,317
  Issued: March 25, 2008
  Inventor(s): Chang; Yunik & Dow; Gordon J.
  Assignee(s): Dow Pharmaceutical Sciences
  An aqueous solution of metronidazole in which the concentration of metronidazole is higher than 0.75%. The solution contains a combination of solubility-enhancing agents, one of which is a cyclodextrin such as beta-cyclodextrin and the second is niacin or niacinamide. Methods of manufacture and therapeutic use of the solution are disclosed.
  
  Patent expiration dates:
  
  
  • February 21, 2022
    
    ✓ 
    Patent use: ONCE A DAY TOPICAL TREATMENT OF THE INFLAMMATORY LESIONS OF ROSACEA
    ✓ 
    Drug product
  
  

See also...

• MetroGel Cream Consumer Information (Wolters Kluwer)
• MetroGel Gel Consumer Information (Wolters Kluwer)
• MetroGel Consumer Information (Cerner Multum)
• Metrogel Topical Advanced Consumer Information (Micromedex)
• Metronidazole Cream Consumer Information (Wolters Kluwer)
• Metronidazole Emulsion Consumer Information (Wolters Kluwer)
• Metronidazole Gel Consumer Information (Wolters Kluwer)
• Metronidazole topical Consumer Information (Cerner Multum)
• Metronidazole vaginal Consumer Information (Cerner Multum)
• Flagyl Vaginal Advanced Consumer Information (Micromedex)
• Neo-Metric Advanced Consumer Information (Micromedex)
• Nidagel Advanced Consumer Information (Micromedex)
• Metronidazole Topical Advanced Consumer Information (Micromedex)
• Metronidazole Vaginal Advanced Consumer Information (Micromedex)
• Metronidazole topical AHFS DI Monographs (ASHP)

Mifeprex

Mifeprex is a brand name of mifepristone, approved by the FDA in the following formulation(s):

MIFEPREX (mifepristone - tablet; oral)

• 
  Manufacturer: DANCO LABS LLC
  
  Approval date: September 28, 2000
  
  Strength(s): 200MG ^[RLD]

Has a generic version of Mifeprex been approved?

No. There is currently no therapeutically equivalent version of Mifeprex available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Mifeprex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Mifeprex.

See also...

• Mifeprex Consumer Information (Wolters Kluwer)
• Mifeprex Consumer Information (Cerner Multum)
• Mifeprex Advanced Consumer Information (Micromedex)
• Mifeprex AHFS DI Monographs (ASHP)
• Mifepristone Consumer Information (Wolters Kluwer)
• Mifepristone Consumer Information (Cerner Multum)
• Mifepristone Advanced Consumer Information (Micromedex)
• Mifepristone AHFS DI Monographs (ASHP)

DuoDote

DuoDote is a brand name of atropine/pralidoxime, approved by the FDA in the following formulation(s):

DUODOTE (atropine; pralidoxime chloride - injectable; intramuscular)

• 
  Manufacturer: MERIDIAN MEDCL
  
  Approval date: September 28, 2006
  
  Strength(s): 2.1MG/0.7ML;600MG/2ML ^[RLD]

Has a generic version of DuoDote been approved?

No. There is currently no therapeutically equivalent version of DuoDote available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of DuoDote. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with DuoDote.

See also...

• DuoDote Consumer Information (Cerner Multum)
• Atropine and pralidoxime Consumer Information (Cerner Multum)

Capastat Sulfate

Capastat Sulfate is a brand name of capreomycin, approved by the FDA in the following formulation(s):

CAPASTAT SULFATE (capreomycin sulfate - injectable; injection)

• 
  Manufacturer: AKORN
  
  Approved Prior to Jan 1, 1982
  
  Strength(s): EQ 1GM BASE/VIAL ^[RLD]

Has a generic version of Capastat Sulfate been approved?

No. There is currently no therapeutically equivalent version of Capastat Sulfate available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Capastat Sulfate. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Capastat Sulfate.

See also...

• Capastat Sulfate Consumer Information (Cerner Multum)
• Capastat Sulfate Advanced Consumer Information (Micromedex)
• Capreomycin Consumer Information (Wolters Kluwer)
• Capreomycin Consumer Information (Cerner Multum)
• Capreomycin Injection Advanced Consumer Information (Micromedex)
• Capreomycin Sulfate AHFS DI Monographs (ASHP)

Carafate

Carafate is a brand name of sucralfate, approved by the FDA in the following formulation(s):

CARAFATE (sucralfate - suspension; oral)

• 
  Manufacturer: APTALIS PHARMA US
  
  Approval date: December 16, 1993
  
  Strength(s): 1GM/10ML ^[RLD]

CARAFATE (sucralfate - tablet; oral)

• 
  Manufacturer: APTALIS PHARMA US
  
  Approved Prior to Jan 1, 1982
  
  Strength(s): 1GM ^[RLD][AB]

Has a generic version of Carafate been approved?

Yes. The following products are equivalent to Carafate:

sucralfate tablet; oral

• 
  Manufacturer: NOSTRUM LABS
  
  Approval date: June 8, 1998
  
  Strength(s): 1GM ^[AB]


• 
  Manufacturer: TEVA
  
  Approval date: March 29, 1996
  
  Strength(s): 1GM ^[AB]

Note: No generic formulation of the following product is available.

• sucralfate - suspension; oral

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Carafate. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Carafate.

See also...

• Carafate Consumer Information (Drugs.com)
• Carafate Consumer Information (Wolters Kluwer)
• Carafate Suspension Consumer Information (Wolters Kluwer)
• Carafate Consumer Information (Cerner Multum)
• Carafate Advanced Consumer Information (Micromedex)
• Carafate AHFS DI Monographs (ASHP)
• Sucralfate Consumer Information (Wolters Kluwer)
• Sucralfate Suspension Consumer Information (Wolters Kluwer)
• Sucralfate Consumer Information (Cerner Multum)
• Sulcrate Suspension Plus Advanced Consumer Information (Micromedex)
• Sucralfate Advanced Consumer Information (Micromedex)
• Sucralfate AHFS DI Monographs (ASHP)

Somavert

Somavert is a brand name of pegvisomant, approved by the FDA in the following formulation(s):

SOMAVERT (pegvisomant - injectable; subcutaneous)

• 
  Manufacturer: PHARMACIA AND UPJOHN
  
  Approval date: March 25, 2003
  
  Strength(s): 10MG/VIAL ^[RLD], 15MG/VIAL ^[RLD], 20MG/VIAL ^[RLD]

Has a generic version of Somavert been approved?

No. There is currently no therapeutically equivalent version of Somavert available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Somavert. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Growth hormone antagonists
  Patent 5,350,836
  Issued: September 27, 1994
  Inventor(s): Kopchick; John J. & Chen; Wen Y.
  Assignee(s): Ohio University
  The present invention relates to antagonists of vertebrate growth hormones obtained by mutation of the third alpha helix of such proteins (especially bovine or human GHs). These mutants have growth inhibitory or other GH-antagonizing effects. These novel hormones may be administered exogenously to animals, or transgenic animals may be made that express the antagonist. Animals have been made which exhibited a reduced growth phenotype.
  
  Patent expiration dates:
  
  
  • September 27, 2011
    
    ✓ 
    Patent use: ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE
  
  



• 
  Growth hormone antagonists
  Patent 5,681,809
  Issued: October 28, 1997
  Inventor(s): Kopchick; John J. & Chen; Wen Y.
  Assignee(s): Ohio University
  The present invention relates to antagonists of vertebrate growth hormones obtained by mutation of the third alpha helix of such proteins (especially bovine or human GHs). These mutants have growth inhibitory or other GH-antagonizing effects. These novel hormones may be administered exogenously to animals, or transgenic animals may be made that express the antagonist. Animals have been made which exhibited a reduced growth phenotype.
  
  Patent expiration dates:
  
  
  • September 27, 2011
    
    ✓ 
    Patent use: ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE
  
  



• 
  Human growth hormone variants
  Patent 5,849,535
  Issued: December 15, 1998
  Inventor(s): Cunningham; Brian C. & Lowman; Henry B. & Wells; James A. & Clark; Ross G. & Olson; Kenneth & Fuh; Germaine G.
  Assignee(s): Genentech, Inc.
  Human growth hormone variants, DNA encoding the variants, vectors, host cells, pegylated forms of the variants, as well as methods of making the variants are disclosed.
  
  Patent expiration dates:
  
  
  • March 25, 2017
    
    ✓ 
    Drug substance
  
  



• 
  Growth hormone receptor antagonists and methods of reducing growth hormone activity in a mammal
  Patent 5,958,879
  Issued: September 28, 1999
  Inventor(s): Kopchick; John J. & Chen; Wen Y.
  Assignee(s): Ohio University/Edison Biotechnology Institute
  The present invention relates to antagonists of vertebrate growth hormones obtained by mutation of the third alpha helix of such proteins (especially bovine or human GHs). These mutants have growth-inhibitory or other GH-antagonizing effects. These novel hormones may be administered exogenously to mammals. The antagonists may be used to reduce the activity of growth hormone in a mammal, especially one suffering from diabetes, diabetic retinopathy, diabetic nephropathy, a growth hormone secreting tumor, acromegaly, or gigantism.
  
  Patent expiration dates:
  
  
  • September 27, 2011
    
    ✓ 
    Patent use: ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE
  
  



• 
  Method for inhibiting growth hormone action
  Patent 6,057,292
  Issued: May 2, 2000
  Inventor(s): Cunningham; Brian C. & Lowman; Henry B. & Wells; James A. & Clark; Ross G. & Olson; Kenneth & Fuh; Germaine G.
  Assignee(s): Genentech, Inc.
  Human growth hormone variants are disclosed having enhanced affinity for the growth hormone receptor. Also disclosed are human growth hormone variants conjugated to one or more chemical groups, such as poly(ethylene glycol), which is believed to prolong the in vivo half-life of the variants.
  
  Patent expiration dates:
  
  
  • September 21, 2015
    
    ✓ 
    Patent use: ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE
  
  



• 
  Methods for treating acromegaly and giantism with growth hormone antagonists
  Patent 6,583,115
  Issued: June 24, 2003
  Inventor(s): John J.; Kopchick & Wen Y.; Chen
  Assignee(s): Ohio University/Edison Biotechnology Institute
  The present invention relates to antagonists of vertebrate growth hormones obtained by mutation of the third alpha helix of such proteins (especially bovine or human GHs). These mutants-have growth-inhibitory or other GH-antagonizing effects. These novel hormones may be administered exogenously to animals, or transgenic animals may be made that express the antagonist. Animals have been made which exhibited a reduced growth phenotype. The invention also describes methods of treating acromegaly, gigantism, cancer, diabetes, vascular eye diseases (diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, retinopathy of sickle-cell anemia, etc.) as well as nephropathy and other diseases, by administering an effective amount of a growth hormone antagonist. The invention also provides pharmaceutical formulations comprising one or more growth hormone antagonists.
  
  Patent expiration dates:
  
  
  • September 27, 2011
    
    ✓ 
    Patent use: ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE
  
  

See also...

• Somavert Consumer Information (Drugs.com)
• Somavert Consumer Information (Wolters Kluwer)
• Somavert Consumer Information (Cerner Multum)
• Somavert Advanced Consumer Information (Micromedex)
• Somavert AHFS DI Monographs (ASHP)
• Pegvisomant Consumer Information (Wolters Kluwer)
• Pegvisomant Consumer Information (Cerner Multum)
• Pegvisomant Subcutaneous Advanced Consumer Information (Micromedex)
• Pegvisomant AHFS DI Monographs (ASHP)

Brevibloc

Brevibloc is a brand name of esmolol, approved by the FDA in the following formulation(s):

BREVIBLOC (esmolol hydrochloride - injectable; injection)

• 
  Manufacturer: BAXTER HLTHCARE CORP
  
  Approval date: February 25, 2003
  
  Strength(s): 10MG/ML ^[RLD][AP]

Has a generic version of Brevibloc been approved?

A generic version of Brevibloc has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Brevibloc and have been approved by the FDA:

esmolol hydrochloride injectable; injection

• 
  Manufacturer: APP PHARMS
  
  Approval date: May 2, 2005
  
  Strength(s): 10MG/ML ^[AP]


• 
  Manufacturer: BEDFORD LABS
  
  Approval date: August 10, 2004
  
  Strength(s): 10MG/ML ^[AP]


• 
  Manufacturer: BIONICHE PHARMA
  
  Approval date: May 2, 2005
  
  Strength(s): 10MG/ML ^[AP]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Brevibloc. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Ready-to-use esmolol solution
  Patent 6,310,094
  Issued: October 30, 2001
  Inventor(s): Liu; Jie & Pejaver; Satish K. & Owoo; George
  Assignee(s): Baxter International Inc.
  A ready-to-use injectable, aqueous pharmaceutical composition for the treatment of cardiac conditions, comprising methyl-3-[4-(2-hydroxy-3-isopropylamino) propoxy] phenylpropionate hydrochloride (esmolol hydrochloride), a buffering agent and an osmotic-adjusting agent, as well as a method for its manufacture in a container, is disclosed.
  
  Patent expiration dates:
  
  
  • January 12, 2021
    
  
  
  
  • July 12, 2021
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Esmolol formulation
  Patent 6,528,540
  Issued: March 4, 2003
  Inventor(s): Jie; Liu & Satish K.; Pejaver & George; Owoo
  Assignee(s): Baxter International Inc.
  An aqueous, sterile pharmaceutical composition suitable for parenteral administration for the treatment of cardiac conditions, comprising methyl-3-[4-(2-hydroxy-3-isopropylamino)propoxy]phenylpropionate hydrochloride (esmolol hydrochloride), a buffering agent and an osmotic-adjusting agent, as well as a method for its manufacture, are disclosed.
  
  Patent expiration dates:
  
  
  • January 12, 2021
    
  
  
  
  • July 12, 2021
    
    ✓ 
    Pediatric exclusivity
  
  

See also...

• Brevibloc Consumer Information (Wolters Kluwer)
• Brevibloc Consumer Information (Cerner Multum)
• Brevibloc Advanced Consumer Information (Micromedex)
• Brevibloc AHFS DI Monographs (ASHP)
• Esmolol Consumer Information (Wolters Kluwer)
• Esmolol Consumer Information (Cerner Multum)
• Esmolol HCl Advanced Consumer Information (Micromedex)
• Esmolol Intravenous Advanced Consumer Information (Micromedex)
• Esmolol Hydrochloride AHFS DI Monographs (ASHP)